Partnership/Divestment Opportunities

Ambrilia is currently looking to partner and/or divest the following assets:

C2L (Octreotide) Formulation

Indication: Acromegaly and carcinoid tumors
Status: Phase III completed and filing imminent
Rights available: US and other major markets incl. Italy, Eastern Europe, Asia (excluding Korea), Japan & South America (excluding Brazil)

Goserelin Formulation

Indication: Hormone sensitive prostate cancer
Status: Phase I/II
Rights available: Worldwide

NGR-Delivery Technology

Indication: Cancer general
Status: Preclinical
Rights available: Worldwide

Other – PSP94 Immunoassay

Indication: Prostate cancer
Status: Clinical proof of concept with research use only kits
Rights available: Worldwide

 

For more information please contact:

 

Richard La Rue, LL.L, D.D.N.
Interim President & CEO
Tel.: (514) 751-2003 ex. 269
e-mail: rlarue@ambrilia.com


 

Financial Reports